High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma

Tao, Ke; Wei, Zhengkai; Xia, Yan; Zhao, Ruihong; Xu, Hong

doi:10.1155/2022/3565676

Cited by 4 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be mentioned that the prognostic significance of SIRPA expression is inconsistent across different cancer types. It has been reported that high SIRPA expression is a favorable factor in colorectal cancer [45], but it is associated with poor prognosis in diffuse large B-cell lymphoma, follicular lymphoma, non-small cell lung cancer, and esophageal carcinoma [46][47][48][49]. A plausible explanation for these opposing findings is that the M1/M2 TAM ratio and/or the tumor-phagocytotic capacity of TAMs in colorectal cancer would likely be higher than those of the second group of tumors where high SIRPA expression correlates with poor outcome.…”

Section: Prognostic Significance Of Cd47 and Sirpa Expression In High...mentioning

confidence: 99%

A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma

Tang,

Shimada,

Ikegaki

2024

Current Oncology

View full text Add to dashboard Cite

Neuroblastoma is a pediatric cancer with significant clinical heterogeneity. Despite extensive efforts, it is still difficult to cure children with high-risk neuroblastoma. Immunotherapy is a promising approach to treat children with this devastating disease. We have previously reported that macrophages are important effector cells in high-risk neuroblastoma. In this perspective article, we discuss the potential function of the macrophage inhibitory receptor SIRPA in the homeostasis of tumor-associated macrophages in high-risk neuroblastoma. The ligand of SIRPA is CD47, known as a “don’t eat me” signal, which is highly expressed on cancer cells compared to normal cells. CD47 is expressed on both tumor and stroma cells, whereas SIRPA expression is restricted to macrophages in high-risk neuroblastoma tissues. Notably, high SIRPA expression is associated with better disease outcome. According to the current paradigm, the interaction between CD47 on tumor cells and SIRPA on macrophages leads to the inhibition of tumor phagocytosis. However, data from recent clinical trials have called into question the use of anti-CD47 antibodies for the treatment of adult and pediatric cancers. The restricted expression of SIRPA on macrophages in many tissues argues for targeting SIRPA on macrophages rather than CD47 in CD47/SIRPA blockade therapy. Based on the data available to date, we propose that disruption of the CD47-SIRPA interaction by anti-CD47 antibody would shift the macrophage polarization status from M1 to M2, which is inferred from the 1998 study by Timms et al. In contrast, the anti-SIRPA F(ab’)2 lacking Fc binds to SIRPA on the macrophage, mimics the CD47-SIRPA interaction, and thus maintains M1 polarization. Anti-SIRPA F(ab’)2 also prevents the binding of CD47 to SIRPA, thereby blocking the “don’t eat me” signal. The addition of tumor-opsonizing and macrophage-activating antibodies is expected to enhance active tumor phagocytosis.

show abstract

Section: Prognostic Significance Of Cd47 and Sirpa Expression In High...mentioning

confidence: 99%

A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma

Tang,

Shimada,

Ikegaki

2024

Current Oncology

View full text Add to dashboard Cite

show abstract

“…ThermControl v2.0.4, the melting temperature (TM) and aggregation (TAgg) temperature were determined. 20…”

Section: Stability Analysismentioning

confidence: 99%

“…Exploiting this physiological checkpoint, tumor cells often upregulate CD47 and thereby escape recognition and removal by macrophages (15,16). Similarly, enhanced expression of SIRPα by intratumoral monocytes/macrophages has recently been shown to be associated with poorer survival in 5 follicular lymphoma, colorectal cancer, intrahepatic cholangiocarcinoma, and esophageal cancer (17)(18)(19)(20).…”

Section: Introductionmentioning

confidence: 97%

Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells

Wagner,

Blaess,

Leske

et al. 2023

Preprint

View full text Add to dashboard Cite

Signal-regulatory protein α (SIRPα) expressed by myeloid cells is of particular interest for therapeutic strategies targeting the interaction between SIRPα and the "don't eat me" ligand CD47 and as a marker to monitor macrophage infiltration into tumor lesions. To address both approaches, we developed a set of novel human SIRPα (hSIRPα) -specific nanobodies (Nbs). We identified three high-affinity Nbs targeting the hSIRPα/hCD47 interface, thereby enhancing antibody-dependent cellular phagocytosis (ADCP). For non-invasive in vivo imaging, we chose S36 Nb as a non-modulating binder. By quantitative positron emission tomography (PET) in novel hSIRPα/hCD47 knock-in (KI) mice, we demonstrated the applicability of 64Cu-hSIRPα-S36 Nb to visualize tumor infiltration of myeloid cells. We envision that the hSIRPα-Nbs presented in this study have potential as versatile probes, including novel myeloid-specific checkpoint inhibitors for combinatorial treatment approaches and for in vivo stratification and monitoring of individual responses during cancer immunotherapies.

show abstract

“…This article has been retracted by Hindawi following an investigation undertaken by the publisher [ 1 ]. This investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process: Discrepancies in scope Discrepancies in the description of the research reported Discrepancies between the availability of data and the research described Inappropriate citations Incoherent, meaningless and/or irrelevant content included in the article Peer-review manipulation …”

mentioning

confidence: 99%

“…Tis article has been retracted by Hindawi following an investigation undertaken by the publisher [1]. Tis investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process:…”

mentioning

confidence: 99%

Retracted: High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma

Healthcare Engineering

2023

Journal of Healthcare Engineering

View full text Add to dashboard Cite

High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma

Cited by 4 publications

References 30 publications

A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma

A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma

Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells

Retracted: High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma

Contact Info

Product

Resources

About